Source:http://linkedlifedata.com/resource/pubmed/id/16173961
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2005-9-21
|
| pubmed:abstractText |
We analysed the impact of age and gender on biology and outcome of 2084 patients diagnosed with non-Hodgkin lymphoma (NHL) between October 1986 and December 2002 and treated according to the Berlin-Frankfurt-Münster (BFM) multicentre protocols NHL-BFM-86, -90 and -95. Median age at diagnosis was 8.0 years for 97 precursor B-lymphoblastic lymphoma (pB-LBL) patients, 8.8 years for 335 T-lymphoblastic lymphoma (T-LBL) patients, 8.4 years for 1004 Burkitt's lymphoma/leukaemia (BL/B-AL) patients, 11.4 years for 173 diffuse large B-cell lymphoma (centroblastic subtype) (DLBCL-CB) patients, 13.2 years for 40 primary mediastinal large B-cell lymphoma (PMLBL) patients and 10.8 years for 215 anaplastic large-cell lymphoma (ALCL) patients (P < 0.00001). The male:female ratio was 0.9:1 for pB-LBL and PMLBL, 1.7:1 for DLBCL-CB, 1.8:1 for ALCL, 2.5:1 for T-LBL and 4.5:1 for BL/B-AL (P < 0.00001). The probability of event-free survival at 5 years (5-year pEFS) was 85 +/- 1% for all 2084 patients [median follow-up 5.7 (0.1-15.9) years], and was significantly superior for male T-LBL and DLBCL-CB patients. Comparing age-groups 0-4, 5-9, 10-14 and 15-18 years, pEFS was inferior for the youngest patients only in the pB-LBL- and ALCL-groups. T-LBL and DLBCL-CB adolescent females had worse outcome than younger girls while age had no impact on pEFS for boys. We conclude that the distribution of age and gender differed between NHL-subtypes. The impact of gender on outcome differed between NHL subgroups. The prognostic impact of age differed not only by NHL-subtype but also according to gender in some subtypes.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/6-Mercaptopurine,
http://linkedlifedata.com/resource/pubmed/chemical/Asparaginase,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0007-1048
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
131
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
39-49
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16173961-6-Mercaptopurine,
pubmed-meshheading:16173961-Adolescent,
pubmed-meshheading:16173961-Age Factors,
pubmed-meshheading:16173961-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16173961-Asparaginase,
pubmed-meshheading:16173961-Child,
pubmed-meshheading:16173961-Child, Preschool,
pubmed-meshheading:16173961-Cyclophosphamide,
pubmed-meshheading:16173961-Cytarabine,
pubmed-meshheading:16173961-Disease-Free Survival,
pubmed-meshheading:16173961-Female,
pubmed-meshheading:16173961-Humans,
pubmed-meshheading:16173961-Infant,
pubmed-meshheading:16173961-Lymphoma, Non-Hodgkin,
pubmed-meshheading:16173961-Male,
pubmed-meshheading:16173961-Methotrexate,
pubmed-meshheading:16173961-Multivariate Analysis,
pubmed-meshheading:16173961-Prednisone,
pubmed-meshheading:16173961-Regression Analysis,
pubmed-meshheading:16173961-Sex Factors,
pubmed-meshheading:16173961-Survival Rate,
pubmed-meshheading:16173961-Vincristine
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence.
|
| pubmed:affiliation |
Department of Paediatric Haematology and Oncology, Children's University Hospital, Giessen, Germany.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|